# Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta

Source: https://onco.cc/trials/nct07621718/  
OnCo record `nct07621718` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zoldonrasib, CAPOX, FLOT in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) is a phase 3 interventional study registered as NCT07621718 by Revolution Medicines, Inc., with 670 participants planned, started 2026-05-22 and due to reach its primary completion in 2028-12-30. Interventions recorded: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: RASolute 305
- Tags: ctgov-ingest
- Registry id: NCT07621718
- Phase: 3
- Setting: RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 670

## Notes

- RASolute 305 (registry, 24 September 2026): phase 3, double-blind, investigator's choice of modified FOLFIRINOX or gemcitabine plus nab-paclitaxel with or without zoldonrasib as first-line treatment for metastatic KRAS G12D-mutated pancreatic adenocarcinoma; 670 participants (estimated), recruiting, started 22 May 2026, primary completion December 2028; United States sites only so far.

## Sources

- ClinicalTrials.gov NCT07621718: https://clinicaltrials.gov/study/NCT07621718

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/), [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- ideas: [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [Off-the-shelf KRAS vaccines after pancreatic cancer surgery](https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/)

---
JSON: https://onco.cc/api/v1/entities/nct07621718.json